Stock Watch: Reinforcements Required As Darzalex Carries J&J
With Greater Concentration Comes Greater Responsibility For Growth
Loss of exclusivity and other competitive pressures will continue to offset J&J’s pharmaceutical growth as its former blockbusters accumulate in ex-growth "other" categories. Can the pipeline take up the slack?
You may also be interested in...
J&J/Legend’s Carvykti Data Show Earlier-Line Efficacy As Commercial Headwinds Remain
The companies unblinded data from CARTITUDE-4, which met its primary endpoint, but analysts citing KOLs said they continue to face issues with limited manufacturing slots and out-of-spec product.
BeiGene’s Brukinsa Set To Take On Imbruvica With CLL Approval
The BTK inhibitor demonstrated superiority to AbbVie/J&J’s Imbruvica for overall response in relapsed/refractory CLL, in addition to hitting a progression-free survival endpoint versus chemotherapy in the first-line.
Stock Watch: Post-Pandemic Drug Commercialization Shifts
Emerging from the pandemic after nearly three years, therapy areas and drug classes are traveling at different speeds.